1
|
Moutaouakkil Y, el Jaoudi R, Adouani B, Tadlaoui Y, Serragui S, Ait el cadi M, Cherrah Y, Lamsaouri J, Bousliman Y. Pharmacovigilance de la chimioprophylaxie de longue durée à la méfloquine. TOXICOLOGIE ANALYTIQUE ET CLINIQUE 2019. [DOI: 10.1016/j.toxac.2018.12.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Kemirembe K, Cabrera M, Cui L. Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum. INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE 2017; 7:131-137. [PMID: 28319724 PMCID: PMC5358947 DOI: 10.1016/j.ijpddr.2017.03.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Revised: 03/04/2017] [Accepted: 03/08/2017] [Indexed: 12/18/2022]
Abstract
The 8-aminoquinoline tafenoquine (TFQ), a primaquine derivative, is currently in late-stage clinical development for the radical cure of P. vivax. Here drug interactions between TFQ and chloroquine and six artemisinin-combination therapy (ACT) partner drugs in P. falciparum asexual stages and gametocytes were investigated. TFQ was mostly synergistic with the ACT-partner drugs in asexual parasites regardless of genetic backgrounds. However, at fixed ratios of 1:3, 1:1 and 3:1, TFQ only interacted synergistically with naphthoquine, pyronaridine and piperaquine in gametocytes. This study indicated that TFQ and ACT-partner drugs will likely have increased potency against asexual stages of the malaria parasites, whereas some drugs may interfere with each other against the P. falciparum gametocytes.
Collapse
Affiliation(s)
- Karen Kemirembe
- Department of Entomology, The Pennsylvania State University, University Park, PA 16802, USA
| | - Mynthia Cabrera
- Department of Entomology, The Pennsylvania State University, University Park, PA 16802, USA
| | - Liwang Cui
- Department of Entomology, The Pennsylvania State University, University Park, PA 16802, USA.
| |
Collapse
|
3
|
Giovanella F, Ferreira GK, de Prá SDT, Carvalho-Silva M, Gomes LM, Scaini G, Gonçalves RC, Michels M, Galant LS, Longaretti LM, Dajori AL, Andrade VM, Dal-Pizzol F, Streck EL, de Souza RP. Effects of primaquine and chloroquine on oxidative stress parameters in rats. AN ACAD BRAS CIENC 2015; 87:1487-96. [PMID: 26312430 DOI: 10.1590/0001-3765201520140637] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Primaquine and chloroquine are used for the treatment of malaria; evidence from the literature suggests that these drugs may induce oxidative stress. In this study we investigated the effects of primaquine and chloroquine on oxidative damage and DNA damage in brain, liver and kidney of rats after 7, 14 and 21 days of administration. Our results demonstrated that primaquine causes DNA damage in brain after 7, 14 and 21 days, and in liver after 7 and 14 days. Moreover, primaquine increases TBARS levels in the kidney and protein carbonyls in the brain after 14 days, and decreases protein carbonyls in the liver after 7 days. Whereas chloroquine causes DNA damage in the kidney after 7 and 14 days, and in the liver after 14 and 21 days, increases TBARS levels in the kidney after 7 days, and decreases TBARS levels in the brain after 21 days. Moreover, decreases protein carbonyls in the liver after 7 and 14 days, and in the brain after 7 and 21 days. However, chloroquine treatment for 14 days increases protein carbonyls in the brain and kidney. In conclusion, these results showed that prolonged treatment with antimalarial may adversely affect the DNA.
Collapse
Affiliation(s)
| | | | | | | | - Lara M Gomes
- Universidade do Extremo Sul Catarinense, Criciúma, SC, BR
| | - Giselli Scaini
- Universidade do Extremo Sul Catarinense, Criciúma, SC, BR
| | - Renata C Gonçalves
- Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Porto Alegre, RS, BR
| | - Monique Michels
- Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Porto Alegre, RS, BR
| | - Letícia S Galant
- Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Porto Alegre, RS, BR
| | | | | | | | - Felipe Dal-Pizzol
- Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Porto Alegre, RS, BR
| | | | | |
Collapse
|
4
|
Campo B, Vandal O, Wesche DL, Burrows JN. Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog Glob Health 2015; 109:107-22. [PMID: 25891812 PMCID: PMC4455353 DOI: 10.1179/2047773215y.0000000013] [Citation(s) in RCA: 72] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The eradication of malaria will only be possible if effective, well-tolerated medicines kill hypnozoites in vivax and ovale malaria, and thus prevent relapses in patients. Despite progress in the 8-aminoquinoline series, with tafenoquine in Phase III showing clear benefits over primaquine, the drug discovery challenge to identify hypnozoiticidal or hypnozoite-activating compounds has been hampered by the dearth of biological tools and assays, which in turn has been limited by the immense scientific and logistical challenges associated with accessing relevant human tissue and sporozoites. This review summarises the existing drug discovery series and approaches concerning the goal to block relapse.
Collapse
Affiliation(s)
- Brice Campo
- Medicines for Malaria Venture, Geneva, Switzerland
| | - Omar Vandal
- The Bill and Melinda Gates Foundation, Seattle, WA, USA
| | - David L. Wesche
- The Bill and Melinda Gates Foundation, Seattle, WA, USA
- Great Lakes Drug Development/Certara, Princeton, NJ, USA
| | | |
Collapse
|
5
|
Design and Synthesis of Novel Hybrid Molecules against Malaria. INTERNATIONAL JOURNAL OF MEDICINAL CHEMISTRY 2015; 2015:458319. [PMID: 25734014 PMCID: PMC4334980 DOI: 10.1155/2015/458319] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 12/05/2014] [Accepted: 12/10/2014] [Indexed: 01/26/2023]
Abstract
The effective treatment of malaria can be very complex: Plasmodium parasites develop in multiple stages within a complex life cycle between mosquitoes as vectors and vertebrates as hosts. For the full and effective elimination of parasites, an effective drug should be active against the earliest stages of the Plasmodium infection: liver stages (reduce the progress of the infection), blood stages (cure the clinical symptoms), and gametocytes (inhibit the transmission cycle). Towards this goal, here we report the design, the synthetic methodology, and the characterization of novel hybrid agents with combined activity against Plasmodium liver stages and blood stages and gametocytes. The divergent synthetic approach allows the access to differently linked primaquine-chloroquine hybrid templates in up to eight steps.
Collapse
|
6
|
Herath HMTB, McChesney JD, Walker LA, Nanayakkara NPD. Synthesis of [13C6]primaquine. J Labelled Comp Radiopharm 2013; 56:341-3. [PMID: 24285435 DOI: 10.1002/jlcr.3039] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Accepted: 01/26/2013] [Indexed: 11/08/2022]
Abstract
In support of a program to identify toxic metabolites of the antimalarial, primaquine, its [(13)C6] analog was prepared from [(13)C6] anisole in seven steps.
Collapse
Affiliation(s)
- H M T Bandara Herath
- National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, MS, 38677, USA
| | | | | | | |
Collapse
|
7
|
G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 2012; 9:e1001339. [PMID: 23152723 PMCID: PMC3496665 DOI: 10.1371/journal.pmed.1001339] [Citation(s) in RCA: 360] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2012] [Accepted: 10/04/2012] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND Primaquine is a key drug for malaria elimination. In addition to being the only drug active against the dormant relapsing forms of Plasmodium vivax, primaquine is the sole effective treatment of infectious P. falciparum gametocytes, and may interrupt transmission and help contain the spread of artemisinin resistance. However, primaquine can trigger haemolysis in patients with a deficiency in glucose-6-phosphate dehydrogenase (G6PDd). Poor information is available about the distribution of individuals at risk of primaquine-induced haemolysis. We present a continuous evidence-based prevalence map of G6PDd and estimates of affected populations, together with a national index of relative haemolytic risk. METHODS AND FINDINGS Representative community surveys of phenotypic G6PDd prevalence were identified for 1,734 spatially unique sites. These surveys formed the evidence-base for a Bayesian geostatistical model adapted to the gene's X-linked inheritance, which predicted a G6PDd allele frequency map across malaria endemic countries (MECs) and generated population-weighted estimates of affected populations. Highest median prevalence (peaking at 32.5%) was predicted across sub-Saharan Africa and the Arabian Peninsula. Although G6PDd prevalence was generally lower across central and southeast Asia, rarely exceeding 20%, the majority of G6PDd individuals (67.5% median estimate) were from Asian countries. We estimated a G6PDd allele frequency of 8.0% (interquartile range: 7.4-8.8) across MECs, and 5.3% (4.4-6.7) within malaria-eliminating countries. The reliability of the map is contingent on the underlying data informing the model; population heterogeneity can only be represented by the available surveys, and important weaknesses exist in the map across data-sparse regions. Uncertainty metrics are used to quantify some aspects of these limitations in the map. Finally, we assembled a database of G6PDd variant occurrences to inform a national-level index of relative G6PDd haemolytic risk. Asian countries, where variants were most severe, had the highest relative risks from G6PDd. CONCLUSIONS G6PDd is widespread and spatially heterogeneous across most MECs where primaquine would be valuable for malaria control and elimination. The maps and population estimates presented here reflect potential risk of primaquine-associated harm. In the absence of non-toxic alternatives to primaquine, these results represent additional evidence to help inform safe use of this valuable, yet dangerous, component of the malaria-elimination toolkit. Please see later in the article for the Editors' Summary.
Collapse
|
8
|
Dow GS, Magill AJ, Ohrt C. Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. Ther Clin Risk Manag 2011; 4:803-19. [PMID: 19209263 PMCID: PMC2621393 DOI: 10.2147/tcrm.s1025] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Malaria is of continuing concern in nonimmune traveling populations. Traditionally, antimalarial drugs have been developed as agents for dual indications (treatment and prophylaxis). However, since 2000, when the 5th Amendment to the Declaration of Helsinki (DH2000) was adopted, development of new malaria prophylaxis drugs in this manner has ceased. As a consequence, there may not be any new drugs licensed for this indication in the foreseeable future. Major pharmaceutical companies have interpreted DH2000 to mean that the traditional development paradigm may be considered unethical because of doubt over the likelihood of benefit to endemic populations participating in clinical studies, the use of placebo, and the sustainability of post-trial access to study medications. In this article, we explore the basis of these concerns and suggest that the traditional development paradigm remains ethical under certain circumstances. We also consider alternative approaches that may be more attractive to sponsors as they either do not use placebo, or utilize populations in endemic countries who may unambiguously benefit. These approaches represent the way forward in the future, but are at present unproven in clinical practice, and face numerous regulatory, logistical and technical challenges. Consequently, in the short term, we argue that the traditional clinical development paradigm remains the most feasible approach and is ethical and consistent with the spirit of DH2000 under the appropriate circumstances.
Collapse
Affiliation(s)
- Geoffrey S Dow
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
| | | | | |
Collapse
|
9
|
Discovery of potent, novel, non-toxic anti-malarial compounds via quantum modelling, virtual screening and in vitro experimental validation. Malar J 2011; 10:274. [PMID: 21933377 PMCID: PMC3206494 DOI: 10.1186/1475-2875-10-274] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Accepted: 09/20/2011] [Indexed: 11/13/2022] Open
Abstract
Background Developing resistance towards existing anti-malarial therapies emphasize the urgent need for new therapeutic options. Additionally, many malaria drugs in use today have high toxicity and low therapeutic indices. Gradient Biomodeling, LLC has developed a quantum-model search technology that uses quantum similarity and does not depend explicitly on chemical structure, as molecules are rigorously described in fundamental quantum attributes related to individual pharmacological properties. Therapeutic activity, as well as toxicity and other essential properties can be analysed and optimized simultaneously, independently of one another. Such methodology is suitable for a search of novel, non-toxic, active anti-malarial compounds. Methods A set of innovative algorithms is used for the fast calculation and interpretation of electron-density attributes of molecular structures at the quantum level for rapid discovery of prospective pharmaceuticals. Potency and efficacy, as well as additional physicochemical, metabolic, pharmacokinetic, safety, permeability and other properties were characterized by the procedure. Once quantum models are developed and experimentally validated, the methodology provides a straightforward implementation for lead discovery, compound optimizzation and de novo molecular design. Results Starting with a diverse training set of 26 well-known anti-malarial agents combined with 1730 moderately active and inactive molecules, novel compounds that have strong anti-malarial activity, low cytotoxicity and structural dissimilarity from the training set were discovered and experimentally validated. Twelve compounds were identified in silico and tested in vitro; eight of them showed anti-malarial activity (IC50 ≤ 10 μM), with six being very effective (IC50 ≤ 1 μM), and four exhibiting low nanomolar potency. The most active compounds were also tested for mammalian cytotoxicity and found to be non-toxic, with a therapeutic index of more than 6,900 for the most active compound. Conclusions Gradient's metric modelling approach and electron-density molecular representations can be powerful tools in the discovery and design of novel anti-malarial compounds. Since the quantum models are agnostic of the particular biological target, the technology can account for different mechanisms of action and be used for de novo design of small molecules with activity against not only the asexual phase of the malaria parasite, but also against the liver stage of the parasite development, which may lead to true causal prophylaxis.
Collapse
|
10
|
Murambiwa P, Masola B, Govender T, Mukaratirwa S, Musabayane C. Anti-malarial drug formulations and novel delivery systems: a review. Acta Trop 2011; 118:71-9. [PMID: 21439929 DOI: 10.1016/j.actatropica.2011.03.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2011] [Revised: 03/15/2011] [Accepted: 03/16/2011] [Indexed: 10/18/2022]
Abstract
Artemisinin combination therapies have decreased malaria associated morbidity and mortality in several parts of the world. On the other hand, malaria cases have increased in sub-Saharan Africa largely due to falciparum resistance to the most frequently used drugs (chloroquine and sulphadoxine/pyrimethamine (SP) combination). Therapeutic failure has also been attributed in part to adverse effects of anti-malarial drugs and patients' non-compliance due to inconvenient dosing schedules. We consider that formulation and evaluation of novel drug delivery systems is not only less expensive than developing new drugs, but may also improve delivery of anti-malarials at the desired rates. In this review we evaluate the therapeutic efficacy of existing anti-malarial drugs and assess the feasibility of developing novel formulations and delivery systems.
Collapse
|
11
|
Na-Bangchang K, Karbwang J. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fundam Clin Pharmacol 2009; 23:387-409. [PMID: 19709319 DOI: 10.1111/j.1472-8206.2009.00709.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Antimalarial drugs have played a mainstream role in controlling the spread of malaria through the treatment of patients infected with the plasmodial parasites and controlling its transmissibility. The inadequate armory of drugs in widespread use for the treatment of malaria, development of strains resistant to currently used antimalarials, and the lack of affordable new drugs are the limiting factors in the fight against malaria. In addition, other problems with some existing agents include unfavorable pharmacokinetic properties and adverse effects/toxicity. These factors underscore the continuing need of research for new classes of antimalarial agents, and a re-examination of the existing antimalarial drugs that may be effective against resistant strains. In recent years, major advances have been made in the pharmacology of several antimalarial drugs both in pharmacokinetics and pharmacodynamics aspects. These include the design, development, and optimization of appropriate dosage regimens of antimalarials, basic knowledge in metabolic pathways of key antimalarials, as well as the elucidation of mechanisms of action and resistance of antimalarials. Pharmacologists have been working in close collaboration with scientists in other disciplines of science/biomedical sciences for more understanding on the biology of the parasite, host, in order to exploit rational design of drugs. Multiple general approaches to the identification of new antimalarials are being pursued at this time. All should be implemented in parallel with focus on the rational development of new agents directed against newly identified parasite targets. With major advances in our understanding of malaria parasite biology coupled with the completion of the malaria genome, has presented exciting opportunities for target-based antimalarial drug discovery.
Collapse
Affiliation(s)
- Kesara Na-Bangchang
- Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Pathumtanee, Thailand.
| | | |
Collapse
|
12
|
Weissbuch I, Leiserowitz L. Interplay Between Malaria, Crystalline Hemozoin Formation, and Antimalarial Drug Action and Design. Chem Rev 2008; 108:4899-914. [DOI: 10.1021/cr078274t] [Citation(s) in RCA: 140] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Isabelle Weissbuch
- Department of Materials and Interfaces, The Weizmann Institute of Science, 76100-Rehovot, Israel
| | - Leslie Leiserowitz
- Department of Materials and Interfaces, The Weizmann Institute of Science, 76100-Rehovot, Israel
| |
Collapse
|
13
|
Elmes N, Nasveld P, Kitchener S, Kocisko D, Edstein M. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Trans R Soc Trop Med Hyg 2008; 102:1095-101. [DOI: 10.1016/j.trstmh.2008.04.024] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2008] [Revised: 04/15/2008] [Accepted: 04/17/2008] [Indexed: 11/15/2022] Open
|
14
|
Abstract
Malaria remains an important cause of global morbidity and mortality. As antimalarial drug resistance escalates, new safe and effective medications are necessary to prevent and treat malarial infection. Tafenoquine is an 8-aminoquinoline antimalarial that is presently under development. It has a long half-life of approximately 14 days and is generally safe and well tolerated, although it cannot be used in pregnant women and individuals who are deficient in the enzyme glucose-6-phosphate dehydrogenase. In well-designed studies, tafenoquine was highly effective in both the radical cure of relapsing malaria and causal prophylaxis of Plasmodium vivax and P. falciparum infections with protective efficacies of > or = 90%. Given its causal activity and safety profile, tafenoquine represents a potentially exciting alternative to standard agents for the prevention and radical cure of malaria.
Collapse
Affiliation(s)
- Maryanne Crockett
- The Hospital for Sick Children, Division of Infectious Diseases, 555 University Avenue, Toronto, M5G 1X8, Canada.
| | | |
Collapse
|
15
|
Franco-Paredes C, Santos-Preciado JI. Problem pathogens: prevention of malaria in travellers. THE LANCET. INFECTIOUS DISEASES 2006; 6:139-49. [PMID: 16500595 DOI: 10.1016/s1473-3099(06)70410-8] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Human infection with Plasmodium spp leading to clinical episodes of malaria probably began very early in the history of humankind and has persistently inflicted disease among human populations. Malaria is currently considered the world's most important parasitic infection. The global impact of malaria is incalculable and appears to be worsening over the past decades. Although most of this burden of disease is carried by developing tropical countries, cases of imported malaria acquired by international travel are increasingly reported. These numbers are growing because of increased travel to malaria-endemic areas and also due to increased risk of transmission in these areas. Indeed, travel has contributed to the global spread of malaria during the history of humankind. Travellers visiting malaria risk areas should use both personal protective measures and chemoprophylaxis. Non-adherence to chemoprophylactic regimens is frequently secondary to drug side-effects. Therefore, a careful risk-benefit analysis on the use of antimalarial prophylaxis should be carried out in every individual travelling to malaria risk areas. Standby malaria self-treatment represents an alternative in some travellers. However, carefully selected and geographically specific antimalarial drug regimens should be recommended to non-immune people travelling to high-risk areas.
Collapse
Affiliation(s)
- Carlos Franco-Paredes
- Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
| | | |
Collapse
|
16
|
Londoño B, Arango E, Zapata C, Herrera S, Saez J, Blair S, Carmona-Fonseca J. Effect ofSolanum nudum Dunal (Solanaceae) steroids on hepatic trophozoites ofPlasmodium vivax. Phytother Res 2006; 20:267-73. [PMID: 16557608 DOI: 10.1002/ptr.1849] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Steroids isolated from the plant Solanum nudum showed antiplasmodial activity against the blood stages of Plasmodium falciparum. It has been demonstrated that these steroids are neither mutagenic in vitro nor clastogenic in vivo. This study evaluated the effect of five steroids of S. nudum (SN-1, SN-2, SN-3, SN-4 and SN-5) on hepatic trophozoites of P. vivax, using an experimental design, non-balanced, with blind determination of the effect expressed as the percentage reduction of hepatic trophozoites. The sporozoites used to inoculate human hepatoma cells HepG2-A16 were obtained from gametocytemic blood of volunteers infected only with P. vivax, and passed into laboratory-reared Anopheles albimanus mosquitoes. Steroids were added at three different doses (100, 10 and 1 microg/mL) just after inoculation of the cells with sporozoites. The effect was determined by indirect immunofluorescence assays using the monoclonal antibodies Pv210 or Pv47E-2E10 and steroid cytotoxicity on HepG2-A16 cells was assessed by the MTT method. All the steroids reduced the number of hepatic P. vivax trophozoites, SN-2 and SN-4 reduced the number of hepatic trophozoites by 47% and 39% (p < 0.05), respectively.
Collapse
Affiliation(s)
- Berlin Londoño
- Grupo Malaria, Universidad de Antioquia, Medellín, Colombia
| | | | | | | | | | | | | |
Collapse
|
17
|
Yeom JS, Ryu SH, Oh S, Choi DH, Song KJ, Oh YH, Lee JH, Kim YA, Ahn SY, Yang HY, Cha JE, Park JW. Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. J Korean Med Sci 2005; 20:707-12. [PMID: 16224140 PMCID: PMC2779263 DOI: 10.3346/jkms.2005.20.5.707] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Vivax malaria was endemic on the Korean peninsula for many centuries until the late 1970's when the Republic of Korea (ROK) was declared "malaria free". Since its re-emergence in 1993, the number of malaria cases in the military increased exponentially through 2000 near the demilitarized zone. Chemoprophylaxis with chloroquine and primaquine has been used in the ROK Army since 1997 in an attempt to reduce the number of the malaria cases throughout the ROK. Data show that chemoprophylaxis contributed, in part, to the decrease in the number of malaria cases among military personnel. However, mass chemoprophylaxis on a large scale in the ROK Army is unprecedented and extensive supervision and monitoring is warranted to determine its effectiveness and to monitor the appearance of chloroquine tolerant/resistant strains of Plasmodium vivax.
Collapse
Affiliation(s)
- Joon-Sup Yeom
- Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Seung-Ho Ryu
- Department of Occupational Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Sejoong Oh
- Korean Armed Forces, Daegu Hospital, Daegu, Korea
| | - Dong-Hyun Choi
- Department of Surgery, Kyunghee University College of Medicine, Seoul, Korea
| | - Kyoung-Jun Song
- Department of Emergency Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Young-Ha Oh
- Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
| | - Jae-Hyun Lee
- Department of Microbiology, Gachon Medical School, Incheon, Korea
| | - Young-A Kim
- Department of Microbiology, Gachon Medical School, Incheon, Korea
| | - Sun-Young Ahn
- Department of Microbiology, Gachon Medical School, Incheon, Korea
| | - Hwa-Young Yang
- Department of Microbiology, Gachon Medical School, Incheon, Korea
| | - Je-Eun Cha
- Department of Microbiology, Gachon Medical School, Incheon, Korea
| | - Jae-Won Park
- Department of Microbiology, Gachon Medical School, Incheon, Korea
| |
Collapse
|
18
|
Barnett ED, Chen LH. Prevention of travel-related infectious diseases in families of internationally adopted children. Pediatr Clin North Am 2005; 52:1271-86, vi. [PMID: 16154463 PMCID: PMC7118974 DOI: 10.1016/j.pcl.2005.06.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Pretravel consultation before international adoption must encompass standard advice for those who travel, advice for those who are exposed to the newly adopted child, and information about caring for a new child during travel. Children who travel to meet siblings may need special accommodations before and during travel. Data on the health of internationally adopted children illustrate the risk of exposing family members and close contacts to some infectious diseases during or after international adoption. Parents, family members, and close contacts of the newly adopted child should be given advice to reduce their own and their child's risk. Targeted preadoption counseling, close attention to hygiene and safety advice, and prompt identification and treatment of infections lead to the safest and most trouble-free adoption travel experience.
Collapse
Affiliation(s)
- Elizabeth D Barnett
- Maxwell Finland Laboratory for Infectious Diseases, Room 503, Boston Medical Center, 774 Albany Street, Boston, MA 02118, USA
| | | |
Collapse
|
19
|
Bowman ZS, Morrow JD, Jollow DJ, McMillan DC. Primaquine-Induced Hemolytic Anemia: Role of Membrane Lipid Peroxidation and Cytoskeletal Protein Alterations in the Hemotoxicity of 5-Hydroxyprimaquine. J Pharmacol Exp Ther 2005; 314:838-45. [PMID: 15840764 DOI: 10.1124/jpet.105.086488] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Primaquine-induced hemolytic anemia is a toxic side effect that is due to premature splenic sequestration of intact erythrocytes. Previous studies have suggested that a phenolic metabolite, 5-hydroxyprimaquine (5-HPQ), mediates primaquine hemotoxicity by generating reactive oxygen species (ROS) within erythrocytes that overwhelm antioxidant defenses. However, the nature of the oxidative stress is not understood, and the molecular targets, whether protein and/or lipid, are unknown. To investigate the mechanism underlying the hemolytic activity of 5-HPQ, we have examined the effect of hemolytic concentrations of 5-HPQ on ROS formation within rat erythrocytes using the cellular ROS probe, 2',7'-dichlorodihydrofluoresein diacetate. In addition, we examined the effect of 5-HPQ on membrane lipids and cytoskeletal proteins. The data indicate that 5-HPQ causes a prolonged, concentration-dependent generation of ROS within erythrocytes. Interestingly, 5-HPQ-generated ROS was not associated with the onset of lipid peroxidation or an alteration in phosphatidylserine asymmetry. Instead, 5-HPQ induced oxidative injury to the erythrocyte cytoskeleton, as evidenced by changes in the normal electrophoretic pattern of membrane ghost proteins. Immunoblotting with an anti-hemoglobin antibody revealed that these changes were due primarily to the formation of disulfide-linked hemoglobin-skeletal protein adducts. The data suggest that cytoskeletal protein damage, rather than membrane lipid peroxidation or loss of phosphatidylserine asymmetry, underlies the process of removal of erythrocytes exposed to 5-HPQ.
Collapse
Affiliation(s)
- Zachary S Bowman
- Dept. of Cell and Molecular Pharmacology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425, USA
| | | | | | | |
Collapse
|
20
|
Abstract
Malaria prevention has benefited from many diverse disciplines of research, including epidemiologic monitoring, development of laboratory techniques, assessment of insect repellents, or pharmaceutical innovations. Strategies in all these sectors have been explored in recent years, resulting in improved options to prevent travelers' malaria. The addition of atovaquone-proguanil for malaria chemoprophylaxis and the recommendation of primaquine as primary prophylaxis have been significant advances. Tafenoquine seems promising. Standby treatment recommendations have been refined. Many areas still need better strategies. Problematic areas include chemoprophylaxis for long-term travelers, expatriates, and pregnant women; optimal criteria for terminal prophylaxis; and the prevention of malaria in populations that are least likely to seek pretravel evaluations, such as those visiting friends and relatives in their home countries (VFRs). Finally, research in travel and tropical medicine should continue to focus on additional strategies to confront the ever-widening challenge of drug-resistant malaria.
Collapse
Affiliation(s)
- Lin H Chen
- Department of Medicine, Harvard Medical School, Boston, MA, USA.
| | | |
Collapse
|
21
|
Callahan MV, Hamer DH. On the medical edge: preparation of expatriates, refugee and disaster relief workers, and Peace Corps volunteers. Infect Dis Clin North Am 2005; 19:85-101. [PMID: 15701548 DOI: 10.1016/j.idc.2004.10.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Travelers to extreme environments and those who spend long periods of time in settings with limited health care resources need to have more detailed pretravel screening and education than the routine short-term traveler. Expatriates, relief workers, and Peace Corps volunteers need to receive careful pretravel medical, dental, and psychologic screening before deployment. Knowledge of special risks associated with the environment in which they will be stationed is necessary to provide effective education about ways to reduce or eliminate the risk of illness and death. The travel medicine practitioner should also provide detailed, region-specific recommendations regarding emergency care while traveling in remote regions. Information on foreign medical facilities and practitioners should be gathered in advance and regularly updated. Many fee-for-service directories of overseas medical centers are often out of date and do not include emergency contact information. Once deployed, systems should be in place to ensure the traveler's continued personal safety and maintenance of good health. Although these systems are generally beyond the scope of work of travel medicine providers, it is important for the long-term traveler to be aware of the need to be prepared to deal with unexpected medical events. In the event of an overseas emergency, the travel medicine specialist may be called on to facilitate ground or air medical evacuation to the most appropriate medical center, to communicate treatment priorities and pertinent medical details to foreign medical providers, and to facilitate international air evacuation or repatriation if necessary. In each of these cases, the experience for the patient and the travel health professional is dramatically improved by adhering to risk-reduction measures, such as pretravel screening, pretravel health and safety education, and preparing for emergencies in advance.
Collapse
Affiliation(s)
- Michael V Callahan
- Biodefense and Mass-Casualty Care Center for Integration of Medicine and Innovative Technologies, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02139, USA.
| | | |
Collapse
|
22
|
Minodier P, Noël G, Blanc P, Tsaregorodtseva N, Retornaz K, Garnier J. La chimioprophylaxie antipaludéenne de l'enfant voyageur. Arch Pediatr 2005; 12:53-8. [DOI: 10.1016/j.arcped.2004.10.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2004] [Accepted: 10/14/2004] [Indexed: 11/24/2022]
|
23
|
Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 2004; 42:1359-82. [PMID: 14674788 DOI: 10.2165/00003088-200342150-00004] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Several of the antimalarial drugs are chiral and administered as the racemate. These drugs include chloroquine, hydroxychloroquine, quinacrine, primaquine, mefloquine, halofantrine, lumefantrine and tafenoquine. Quinine and quinidine are also stereoisomers, although they are given separately rather than in combination. From the perspective of antimalarial activity, most of these agents demonstrate little stereoselectivity in their effects in vitro. Mefloquine, on the other hand, displays in vitro stereoselectivity against some strains of P. falciparum, with a eudismic ratio of almost 2 : 1 in favour of the (+)-enantiomer. Additionally, for some of these agents (e.g. halofantrine, primaquine, chloroquine), stereoselectivity has been noted in the ability of the enantiomers to cause certain adverse effects. In recent years, stereospecific analytical methods capable of measuring the individual enantiomers after the administration of racemic drugs have been reported for a number of chiral antimalarial drugs. These assays have revealed that almost all the studied antimalarial drugs display stereoselectivity in their pharmacokinetics, leading to enantioselectivity in their plasma concentrations. Whereas the oral absorption of these agents appears to be non-stereoselective, stereoselectivity is often seen in their volume of distribution and/or clearance. With regard to distribution, plasma protein binding of some chiral antimalarial drugs exhibits a significant degree of stereoselectivity, leading to stereoselective distribution to blood cells and other tissues. Because of their low hepatic extraction ratios, stereoselective plasma protein binding also contributes to the stereoselectivity in the metabolism of these drugs. Chiral metabolites are formed from some parent antimalarial drugs, although stereoselective aspects of the pharmacokinetics of the metabolites are not well understood. It is concluded that knowledge of the stereoselective aspects of these agents may be helpful in better understanding their mechanisms of action and possibly optimising their clinical safety and/or effectiveness.
Collapse
Affiliation(s)
- Dion R Brocks
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
| | | |
Collapse
|
24
|
Mühlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjørup I, Behrens RH, Clerinx J, Björkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C, Kollaritsch H, Kapaun A, Knobloch J, Iversen J, Kotlowski A, Malvy DJM, Kern P, Fry G, Siikamaki H, Schulze MH, Soula G, Paul M, Prat JGI, Lehmann V, Bouchaud O, Cunha SD, Atouguia J, Boecken G. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J 2004; 3:5. [PMID: 15003128 PMCID: PMC385246 DOI: 10.1186/1475-2875-3-5] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2003] [Accepted: 03/08/2004] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Plasmodium vivax is the second most common species among malaria patients diagnosed in Europe, but epidemiological and clinical data on imported P. vivax malaria are limited. The TropNetEurop surveillance network has monitored the importation of vivax malaria into Europe since 1999. OBJECTIVES To present epidemiological and clinical data on imported P. vivax malaria collected at European level. MATERIAL AND METHODS Data of primary cases of P. vivax malaria reported between January 1999 and September 2003 were analysed, focusing on disease frequency, patient characteristics, place of infection, course of disease, treatment and differences between network-member countries. RESULTS Within the surveillance period 4,801 cases of imported malaria were reported. 618 (12.9%) were attributed to P. vivax. European travellers and immigrants were the largest patient groups, but their proportion varied among the reporting countries. The main regions of infection in descending order were the Indian subcontinent, Indonesia, South America and Western and Eastern Africa, as a group accounting for more than 60% of the cases. Regular use of malaria chemoprophylaxis was reported by 118 patients. With 86 (inter-quartile range 41-158) versus 31 days (inter-quartile range 4-133) the median symptom onset was significantly delayed in patients with chemoprophylaxis (p < 0.0001). Common complaints were fever, headache, fatigue, and musculo-skeletal symptoms. All patients survived and severe clinical complications were rare. Hospitalization was provided for 60% and primaquine treatment administered to 83.8% of the patients, but frequencies varied strongly among reporting countries. CONCLUSIONS TropNetEurop data can contribute to the harmonization of European treatment policies.
Collapse
Affiliation(s)
- N Mühlberger
- Institute of Tropical Medicine, Humboldt University, Berlin, Germany
| | - T Jelinek
- Institute of Tropical Medicine, Humboldt University, Berlin, Germany
| | - J Gascon
- Secció Medicina Tropical, Hospital Clinic Barcelona – IDIBAPS., Barcelona, Spain
| | - M Probst
- Department of Medicine (Infectious Diseases), Charité, Humboldt University, Berlin, Germany
| | - T Zoller
- Department of Medicine (Infectious Diseases), Charité, Humboldt University, Berlin, Germany
| | - M Schunk
- Department of Infectious Diseases and Tropical Medicine, University of Munich, Germany
| | - J Beran
- Department of Infectious Diseases, University Hospital Hradec Králové, Czech Republic
| | - I Gjørup
- Department of Infectious Diseases, Rigshospitalet, University of Copenhagen; Denmark
| | - RH Behrens
- Hospital for Tropical Diseases, London, UK
| | - J Clerinx
- Clinical Services, Prins Leopold Instituut voor Tropische Geneeskunde, Antwerp; Belgium
| | - A Björkman
- Department of Medicine, Unit of Infectious Diseases, Karolinska Institute, Stockholm, Sweden
| | - P McWhinney
- Infection and Tropical Medicine, Bradford Royal Infirmary, Bradford, UK
| | - A Matteelli
- Clinica di Malattie Infettive e Tropicali, Universitá di Brescia, Italy
| | - R Lopez-Velez
- Infectious Diseases–Microbiology Department, Tropical Medicine & Clinical Parasitology Unit, Hospital Ramon y Cajal, Madrid, Spain
| | - Z Bisoffi
- Centro per le Malattie Tropicali, Ospedale S. Cuore, Negrar Verona, Italy
| | - U Hellgren
- Division of Infectious Diseases, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden
| | - S Puente
- Sección de Medicina Tropical-Servicio de Enfermedades Infecciosas, Hospital Carlos III- Instituto de Salud Carlos III, Madrid, Spain
| | - ML Schmid
- Department of Infection & Tropical Medicine, Newcastle General Hospital, Newcastle- upon-Tyne, UK
| | - B Myrvang
- Department of Infectious Diseases, Ullevaal University Hospital, Oslo, Norway
| | | | - H Laferl
- 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Kaiser-Franz-Josef-Spital der Stadt Wien, Vienna, Austria
| | - C Hatz
- Swiss Tropical Institute, Basel, Switzerland
| | - H Kollaritsch
- Abteilung fur spezifische Prophylaxe und Tropenmedizin am Institut für Pathophysiologie, University of Vienna, Austria
| | - A Kapaun
- Institut für Tropenhygiene und öffentliches Gesundheitswesen, Universität Heidelberg, Germany
| | - J Knobloch
- Institut für Tropenmedizin, Universitätsklinikum Tübingen, Germany
| | - J Iversen
- Department of Infectious Diseases, Hvidovre Hospital, Hvidovre, Denmark
| | - A Kotlowski
- Department of Tropical Medicine and Epidemiology, Medical University of Gdansk, Interfacultary Institute of Maritime and Tropical Medicine in Gdynia, Poland
| | - DJM Malvy
- Hôpital St André-CHU, Bordeaux, France
| | - P Kern
- Sektion Infektiologie und Klinische Immunologie, Universität Ulm, Germany
| | - G Fry
- Tropical Medical Bureau, Dublin, Ireland
| | - H Siikamaki
- Department of Medicine, Division of Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland
| | - MH Schulze
- 2. Klinik für Innere Medizin, Städtische Kliniken "St. Georg", Leipzig, Germany
| | - G Soula
- Department of Infectious and Tropical Diseases, Hopital Nord CHU, Marseille, France
| | - M Paul
- Department and Clinic of Tropical and Parasitic Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland
| | - J Gómez i Prat
- Unitat de Malalties Tropicals, Importades i Vacunacions Internationales, Institut Català de la Salut, Barcelona, Spain
| | - V Lehmann
- Centre for Tropical Medicine and Imported Infectious Diseases, Haukeland University Hospital, Bergen, Norway
| | - O Bouchaud
- Consultation de médecine tropicale, Hôpital Avicenne, Bobigny, France
| | - S da Cunha
- Consulta de Medicina do Viajante, Departamento de Doenças Infecciosas, Hospital Universitário, Coimbra, Portugal
| | - J Atouguia
- Instituto de Higiena e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal
| | - G Boecken
- The German Navy Institute for Maritime Medicine, Center for Applied Tropical Medicine and Infectious Diseases Epidemiology, Kronshagen, Germany
| |
Collapse
|
25
|
Kain KC. Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone) for the prevention of malaria. BioDrugs 2004; 17 Suppl 1:23-8. [PMID: 12785875 DOI: 10.2165/00063030-200317001-00006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Each year at least 30 000 Western travellers acquire malaria and approximately 1-4% of those who acquire Plasmodium falciparum malaria will die as a result of infection. Almost all cases and fatalities are preventable with the use of measures to reduce mosquito bites and appropriate chemoprophylaxis for those at high risk of infection. There are currently a limited number of licensed drugs available to prevent malaria in travellers. New effective and well tolerated agents are urgently needed because of increasing resistance to antimalarials such as chloroquine and proguanil, and real and perceived intolerance to standard drugs such as mefloquine. A newly licensed antimalarial (atovaquone plus proguanil; Malarone) compares favourably with other drug options, although some prescribers may be unfamiliar with the specific advantages and disadvantages of this antimalarial. This article reviews recent clinical experience and randomised controlled trial data in order to address frequently asked questions about this new combination drug.
Collapse
Affiliation(s)
- Kevin C Kain
- Tropical Disease Unit, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
26
|
Bowman ZS, Oatis JE, Whelan JL, Jollow DJ, McMillan DC. Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. J Pharmacol Exp Ther 2004; 309:79-85. [PMID: 14724225 DOI: 10.1124/jpet.103.062984] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Primaquine is an important antimalarial agent because of its activity against exoerythrocytic forms of Plasmodium spp. Methemoglobinemia and hemolytic anemia, however, are dose-limiting side effects of primaquine therapy. These hemotoxic effects are believed to be mediated by metabolites, although the identity of the toxic specie(s) and the mechanism underlying hemotoxicity have remained unclear. Previous studies showed that an N-hydroxylated metabolite of primaquine, 6-methoxy-8-hydroxylaminoquinoline, was capable of mediating primaquine-induced hemotoxicity. The present studies were undertaken to investigate the hemolytic potential of 5-hydroxyprimaquine (5-HPQ), a phenolic metabolite that has been detected in experimental animals. 5-HPQ was synthesized, isolated by flash chromatography, and characterized by NMR spectroscopy and mass spectrometry. In vitro exposure of (51)Cr-labeled erythrocytes to 5-HPQ induced a concentration-dependent decrease in erythrocyte survival (TC(50) of ca. 40 microM) when the exposed cells were returned to the circulation of isologous rats. 5-HPQ also induced methemoglobin formation and depletion of glutathione (GSH) when incubated with suspensions of rat erythrocytes. Furthermore, when red cell GSH was depleted (>95%) by titration with diethyl maleate to mimic GSH instability in human glucose-6-phosphate dehydrogenase deficiency, a 5-fold enhancement of hemolytic activity was observed. These data indicate that 5-HPQ also has the requisite properties to contribute to the hemotoxicity of primaquine. The relative contribution of N-hydroxy versus phenolic metabolites to the overall hemotoxicity of primaquine remains to be assessed.
Collapse
Affiliation(s)
- Zachary S Bowman
- Department of Pharmacology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA
| | | | | | | | | |
Collapse
|
27
|
Abstract
For travelers malaria represents the principal infectious risk of severe complications and death. Infection during traveling depends on the geographical area visited, the predominant species of parasite, the frequency of resistance to antimalarial agents, and whether preventive measures have been taken. Until a vaccine has been developed, prevention strategies consist of providing travelers with information, the use of barrier methods against vector bites, the correct use of chemoprophylaxis, and the possibility of self-diagnosis and treatment. The choice of chemoprophylaxis regimen should be individualized since no regimen guarantees 100% protection or is free of adverse effects or contraindications. The most effective drugs are doxycycline, atovaquone-proguanil and mefloquine while those producing severe adverse effects with the least frequency are atovaquone-proguanil and doxycycline.
Collapse
Affiliation(s)
- Rogelio López-Vélez
- Medicina Tropical y Parasitología Clínica. Servicio de Enfermedades Infecciosas y Servicio de Microbiología. Hospital Ramón y Cajal. Madrid. España.
| |
Collapse
|
28
|
Abstract
An increasing number of families, including children and the elderly, are seeking more adventurous travel in exotic parts of the world. Holiday destinations now include once-remote regions such as subSaharan Africa and New Guinea. This increase in visits to tropical and subtropical regions, combined with widespread chloroquine-resistant malaria, now places millions of Western travelers at risk of infection annually. At least 30,000 travelers from industrialized countries are reported to contract malaria each year and approximately 1 in 100 travelers who acquire Plasmodium falciparum malaria will die.
Collapse
Affiliation(s)
- Kevin C Kain
- Center for Travel and Tropical Medicine, Toronto General Hospital and University of Toronto, Toronto, Canada
| |
Collapse
|
29
|
Dupouy-Camet J, Yera H, Tourte-Schaeffer C. Problems in prescribing malaria chemoprophylaxis for travelers. Fundam Clin Pharmacol 2003; 17:161-9. [PMID: 12667226 DOI: 10.1046/j.1472-8206.2003.00166.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
To offer effective malaria chemoprophylaxis for travelers in a country, the physician must know the precise status of malaria there (frequency, resistance), determine the degree of exposure to mosquito bites, evaluate the precise clinical condition of the traveler, and improve the traveler's compliance with treatment by providing good information on potential side-effects. These side-effects, sometimes overemphasized in the media, lead to poor compliance, particularly after returning home, and, consequently, increase the risk of acquiring malaria. The recently approved Malarone could overcome these drawbacks. But its cost is high and its wide use could also lead to the emergence of resistant strains. Therefore, training professionals in travel medicine is important in malaria prevention and decrease the prescription of abusive or inaccurate prophylaxis (e.g., most tourists traveling in organized tours in Asia, with no stay in remote malaria endemic areas, do not need any prophylaxis). In addition, prevention of mosquito bites with repellents, impregnated bed nets, and indoor insecticide-dispensing devices is still an important tool for controlling malaria in travelers.
Collapse
Affiliation(s)
- Jean Dupouy-Camet
- Centre de Vaccinations Internationales, Hôpital Cochin, Assistance Publique/Hôpitaux de Paris, 27, rue du Faubourg Saint Jacques - 75014 Paris, France.
| | | | | |
Collapse
|
30
|
Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 2003; 36:541-9. [PMID: 12594633 DOI: 10.1086/367542] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2002] [Accepted: 10/15/2002] [Indexed: 11/03/2022] Open
Abstract
Tafenoquine is a promising new 8-aminoquinoline drug that may be useful for malaria prophylaxis in nonpregnant persons with normal glucose-6-phosphate dehydrogenase (G6PD) function. A randomized, double-blind, placebo-controlled chemoprophylaxis trial was conducted with adult residents of northern Ghana to determine the minimum effective weekly dose of tafenoquine for the prevention of infection by Plasmodium falciparum. The primary end point was a positive malaria blood smear result during the 13 weeks of study drug coverage. Relative to the placebo, all 4 tafenoquine dosages demonstrated significant protection against P. falciparum infection: for 25 mg/week, protective efficacy was 32% (95% confidence interval [CI], 20%-43%); for 50 mg/week, 84% (95% CI, 75%-91%); for 100 mg/week, 87% (95% CI, 78%-93%); and for 200 mg/week, 86% (95% CI, 76%-92%). The mefloquine dosage of 250 mg/week also demonstrated significant protection against P. falciparum infection (protective efficacy, 86%; 95% CI, 72%-93%). There was little difference between study groups in the adverse events reported, and there was no evidence of a relationship between tafenoquine dosage and reports of physical complaints or the occurrence of abnormal laboratory parameters. Tafenoquine dosages of 50, 100, and 200 mg/week were safe, well tolerated, and effective against P. falciparum infection in this study population.
Collapse
|
31
|
Abstract
Long before the advent of modern chemoprophylaxis drugs, many practitioners successfully prevented the debilitating and fatal outcomes associated with infection by the Plasmodium parasites that cause malaria. Today, with effective insect repellents and several excellent medications available for chemoprophylaxis, there has never been a better array of quality products to prevent mosquito bites and infection and to suppress parasites once in the blood stream; however, there are thousands of imported cases into nonendemic countries and scores of deaths and near-fatal outcomes every year in returning travelers, soldiers, immigrants, and refugees. In this article, the author focuses on practical uses of currently available prevention tools.
Collapse
Affiliation(s)
- Alan J Magill
- Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
| |
Collapse
|
32
|
Fischer PR, Bialek R. Prevention of malaria in children. Clin Infect Dis 2002; 34:493-8. [PMID: 11797176 DOI: 10.1086/338257] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2001] [Revised: 10/01/2001] [Indexed: 11/03/2022] Open
Abstract
Although malaria kills approximately 1 million children each year, preventive measures can be effective in limiting the mortality and morbidity associated with malaria. Mosquito bites can be avoided by use of appropriate environmental control and use of protective clothing, bed nets, repellents, and insecticide. Chemoprophylaxis is a mainstay of malaria prevention, and new, effective agents are increasingly available. Rapid, accurate diagnosis and effective medical treatment can help people who become ill with malaria despite their preventive efforts. With careful attention to preventive efforts, malaria should be extremely rare in travelers; similarly, broader implementation of preventive measures could decrease the burden of malaria on residents in areas where it is endemic.
Collapse
Affiliation(s)
- Philip R Fischer
- Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
| | | |
Collapse
|
33
|
Affiliation(s)
- J S Keystone
- Center for Travel and Tropical Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
34
|
Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 2001; 33:226-34. [PMID: 11418883 DOI: 10.1086/321817] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2000] [Revised: 02/21/2001] [Indexed: 11/03/2022] Open
Abstract
As international travel becomes increasingly common and resistance to antimalarial drugs escalates, a growing number of travelers are at risk for contracting malaria. Parasite resistance to chloroquine and proguanil and real or perceived intolerance among patients to standard prophylactic agents such as mefloquine have highlighted the need for new antimalarial drugs. Promising new regimens include atovaquone and proguanil, in combination; primaquine; and a related 8-aminoquinoline, tafenoquine. These agents are active against the liver stage of the malaria parasite and therefore can be discontinued shortly after the traveler leaves an area where malaria is endemic, which encourages adherence to the treatment regimen. Part 1 of this series reviews currently recommended chemoprophylactic drug regimens, and part 2 will focus on 8-aminoquinoline drugs.
Collapse
Affiliation(s)
- K C Kain
- Centre for Travel and Tropical Medicine, Division of Infectious Diseases, Department of Medicine, Toronto General Hospital and University of Toronto, Toronto, Ontario, Canada.
| | | | | |
Collapse
|